The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy
Objectives. The assessment of oxidative stress (OS) in serum relapsing-remitting multiple sclerosis patients treated with II-line immunomodulatory therapy (fingolimod, natalizumab) compared to newly diagnosed patients (de novo group) treated with interferon (IFN) beta and controls. The relationship...
Gespeichert in:
| Veröffentlicht in: | Oxidative medicine and cellular longevity 2017-01, Vol.2017 (2017), p.1-12 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12 |
|---|---|
| container_issue | 2017 |
| container_start_page | 1 |
| container_title | Oxidative medicine and cellular longevity |
| container_volume | 2017 |
| creator | Adamczyk-Sowa, Monika Kasperczyk, Sławomir Wawrzyniak, Sławomir Adamczyk, Bożena |
| description | Objectives. The assessment of oxidative stress (OS) in serum relapsing-remitting multiple sclerosis patients treated with II-line immunomodulatory therapy (fingolimod, natalizumab) compared to newly diagnosed patients (de novo group) treated with interferon (IFN) beta and controls. The relationship between OS parameters and gender, age, disease duration, Expanded Disability Status Scale, annualized relapse rate, MRI lesions in patients treated with II-line. Materials and Methods. One hundred and twenty-one patients with RRMS were enrolled in the study. Patients were divided into groups: de novo group, IFN, fingolimod (FG), natalizumab (NT), and controls. Lipid hydroperoxides (LHP), malondialdehyde (MDA), lipofuscin (LPS), and total oxidative status (TOS) were determined. Results. LHP, MDA, and TOS were lower in NT and FG groups compared to the de novo group. Levels of OS were different between NT and FG patients and the IFN group. Women treated with FG and NT had lower MDA, LPH, and TOS than women who were not treated while in men only LPH was lowered. Positive correlations were found between MDA, LHP, TOS, and ARR in the NT group. Conclusion. The II-line immunomodulatory treatment decreased OS particularly among women. No difference in OS levels was observed between II-line therapy and IFN beta. |
| doi_str_mv | 10.1155/2017/9625806 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5613460</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A555850923</galeid><sourcerecordid>A555850923</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-c76e42a094c9cf13d122916e66578ec6d47c9e4cea495b02d455fc89b999c5503</originalsourceid><addsrcrecordid>eNqNkkFvFCEYhidGY2v15tmQeDHRsTADzHAxaZqqm6ypadczYZlvdmkYWIHZuj_FfyuTXbfqyRMf8PDyvfAWxUuC3xPC2HmFSXMueMVazB8Vp0TQqsRC0MfHGuOT4lmMdxjzuqLkaXFSCVK3vK1Pi5-LNaCrrbKjSsY75Ht0_cN0ebIFdJsCxIi-qqAGSBAiMg7dQhiHvJYMuBTRvUlrdANWbaJxq_IGBpNSrtCX0SazsVlFWwg-mogWAVSCbn9mNivnxgGaDcPo_OC70arkww7ljoLa7J4XT3plI7w4jGfFt49Xi8vP5fz60-zyYl5qKkQqdcOBVgoLqoXuSd2RKrvjwDlrWtC8o40WQDUoKtgSVx1lrNetWAohNGO4Pis-7HU343KATmdXQVm5CWZQYSe9MvLvHWfWcuW3knFSUz4JvDkIBP99hJjkYKIGa5UDP0ZJBKdcNHXFM_r6H_TOj8Fle3L6K0Jz7_SBWikL0rje53v1JCovGGMtw6KqM_VuT-n8uDFAf2yZYDklQ07JkIdkZPzVnzaP8O8oZODtHlgb16l7859ykBno1QOd7XJM618gy8x5</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1942142294</pqid></control><display><type>article</type><title>The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Adamczyk-Sowa, Monika ; Kasperczyk, Sławomir ; Wawrzyniak, Sławomir ; Adamczyk, Bożena</creator><contributor>Romero, Francisco J.</contributor><creatorcontrib>Adamczyk-Sowa, Monika ; Kasperczyk, Sławomir ; Wawrzyniak, Sławomir ; Adamczyk, Bożena ; Romero, Francisco J.</creatorcontrib><description>Objectives. The assessment of oxidative stress (OS) in serum relapsing-remitting multiple sclerosis patients treated with II-line immunomodulatory therapy (fingolimod, natalizumab) compared to newly diagnosed patients (de novo group) treated with interferon (IFN) beta and controls. The relationship between OS parameters and gender, age, disease duration, Expanded Disability Status Scale, annualized relapse rate, MRI lesions in patients treated with II-line. Materials and Methods. One hundred and twenty-one patients with RRMS were enrolled in the study. Patients were divided into groups: de novo group, IFN, fingolimod (FG), natalizumab (NT), and controls. Lipid hydroperoxides (LHP), malondialdehyde (MDA), lipofuscin (LPS), and total oxidative status (TOS) were determined. Results. LHP, MDA, and TOS were lower in NT and FG groups compared to the de novo group. Levels of OS were different between NT and FG patients and the IFN group. Women treated with FG and NT had lower MDA, LPH, and TOS than women who were not treated while in men only LPH was lowered. Positive correlations were found between MDA, LHP, TOS, and ARR in the NT group. Conclusion. The II-line immunomodulatory treatment decreased OS particularly among women. No difference in OS levels was observed between II-line therapy and IFN beta.</description><identifier>ISSN: 1942-0900</identifier><identifier>EISSN: 1942-0994</identifier><identifier>DOI: 10.1155/2017/9625806</identifier><identifier>PMID: 29138683</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Adult ; Biological response modifiers ; Biomarkers ; Care and treatment ; Comparative analysis ; Consent ; Dentistry ; Development and progression ; Female ; Fingolimod Hydrochloride - therapeutic use ; Humans ; Immunomodulation ; Immunomodulators ; Immunosuppressive Agents - therapeutic use ; Interferon ; Investigations ; Lipid Peroxides - blood ; Lipofuscin - blood ; Male ; Malondialdehyde - blood ; Medical research ; Medicine, Experimental ; Monoclonal antibodies ; Multiple sclerosis ; Multiple Sclerosis, Relapsing-Remitting - blood ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Natalizumab - therapeutic use ; Neurochemistry ; Neurology ; Oxidative stress ; Oxidative Stress - drug effects ; Pathogenesis ; Rodents</subject><ispartof>Oxidative medicine and cellular longevity, 2017-01, Vol.2017 (2017), p.1-12</ispartof><rights>Copyright © 2017 Bożena Adamczyk et al.</rights><rights>COPYRIGHT 2017 John Wiley & Sons, Inc.</rights><rights>Copyright © 2017 Bożena Adamczyk et al.; This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2017 Bożena Adamczyk et al. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-c76e42a094c9cf13d122916e66578ec6d47c9e4cea495b02d455fc89b999c5503</citedby><cites>FETCH-LOGICAL-c499t-c76e42a094c9cf13d122916e66578ec6d47c9e4cea495b02d455fc89b999c5503</cites><orcidid>0000-0003-1641-5350</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613460/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613460/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29138683$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Romero, Francisco J.</contributor><creatorcontrib>Adamczyk-Sowa, Monika</creatorcontrib><creatorcontrib>Kasperczyk, Sławomir</creatorcontrib><creatorcontrib>Wawrzyniak, Sławomir</creatorcontrib><creatorcontrib>Adamczyk, Bożena</creatorcontrib><title>The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy</title><title>Oxidative medicine and cellular longevity</title><addtitle>Oxid Med Cell Longev</addtitle><description>Objectives. The assessment of oxidative stress (OS) in serum relapsing-remitting multiple sclerosis patients treated with II-line immunomodulatory therapy (fingolimod, natalizumab) compared to newly diagnosed patients (de novo group) treated with interferon (IFN) beta and controls. The relationship between OS parameters and gender, age, disease duration, Expanded Disability Status Scale, annualized relapse rate, MRI lesions in patients treated with II-line. Materials and Methods. One hundred and twenty-one patients with RRMS were enrolled in the study. Patients were divided into groups: de novo group, IFN, fingolimod (FG), natalizumab (NT), and controls. Lipid hydroperoxides (LHP), malondialdehyde (MDA), lipofuscin (LPS), and total oxidative status (TOS) were determined. Results. LHP, MDA, and TOS were lower in NT and FG groups compared to the de novo group. Levels of OS were different between NT and FG patients and the IFN group. Women treated with FG and NT had lower MDA, LPH, and TOS than women who were not treated while in men only LPH was lowered. Positive correlations were found between MDA, LHP, TOS, and ARR in the NT group. Conclusion. The II-line immunomodulatory treatment decreased OS particularly among women. No difference in OS levels was observed between II-line therapy and IFN beta.</description><subject>Adult</subject><subject>Biological response modifiers</subject><subject>Biomarkers</subject><subject>Care and treatment</subject><subject>Comparative analysis</subject><subject>Consent</subject><subject>Dentistry</subject><subject>Development and progression</subject><subject>Female</subject><subject>Fingolimod Hydrochloride - therapeutic use</subject><subject>Humans</subject><subject>Immunomodulation</subject><subject>Immunomodulators</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Interferon</subject><subject>Investigations</subject><subject>Lipid Peroxides - blood</subject><subject>Lipofuscin - blood</subject><subject>Male</subject><subject>Malondialdehyde - blood</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Monoclonal antibodies</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - blood</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Natalizumab - therapeutic use</subject><subject>Neurochemistry</subject><subject>Neurology</subject><subject>Oxidative stress</subject><subject>Oxidative Stress - drug effects</subject><subject>Pathogenesis</subject><subject>Rodents</subject><issn>1942-0900</issn><issn>1942-0994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkkFvFCEYhidGY2v15tmQeDHRsTADzHAxaZqqm6ypadczYZlvdmkYWIHZuj_FfyuTXbfqyRMf8PDyvfAWxUuC3xPC2HmFSXMueMVazB8Vp0TQqsRC0MfHGuOT4lmMdxjzuqLkaXFSCVK3vK1Pi5-LNaCrrbKjSsY75Ht0_cN0ebIFdJsCxIi-qqAGSBAiMg7dQhiHvJYMuBTRvUlrdANWbaJxq_IGBpNSrtCX0SazsVlFWwg-mogWAVSCbn9mNivnxgGaDcPo_OC70arkww7ljoLa7J4XT3plI7w4jGfFt49Xi8vP5fz60-zyYl5qKkQqdcOBVgoLqoXuSd2RKrvjwDlrWtC8o40WQDUoKtgSVx1lrNetWAohNGO4Pis-7HU343KATmdXQVm5CWZQYSe9MvLvHWfWcuW3knFSUz4JvDkIBP99hJjkYKIGa5UDP0ZJBKdcNHXFM_r6H_TOj8Fle3L6K0Jz7_SBWikL0rje53v1JCovGGMtw6KqM_VuT-n8uDFAf2yZYDklQ07JkIdkZPzVnzaP8O8oZODtHlgb16l7859ykBno1QOd7XJM618gy8x5</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Adamczyk-Sowa, Monika</creator><creator>Kasperczyk, Sławomir</creator><creator>Wawrzyniak, Sławomir</creator><creator>Adamczyk, Bożena</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1641-5350</orcidid></search><sort><creationdate>20170101</creationdate><title>The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy</title><author>Adamczyk-Sowa, Monika ; Kasperczyk, Sławomir ; Wawrzyniak, Sławomir ; Adamczyk, Bożena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-c76e42a094c9cf13d122916e66578ec6d47c9e4cea495b02d455fc89b999c5503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Biological response modifiers</topic><topic>Biomarkers</topic><topic>Care and treatment</topic><topic>Comparative analysis</topic><topic>Consent</topic><topic>Dentistry</topic><topic>Development and progression</topic><topic>Female</topic><topic>Fingolimod Hydrochloride - therapeutic use</topic><topic>Humans</topic><topic>Immunomodulation</topic><topic>Immunomodulators</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Interferon</topic><topic>Investigations</topic><topic>Lipid Peroxides - blood</topic><topic>Lipofuscin - blood</topic><topic>Male</topic><topic>Malondialdehyde - blood</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Monoclonal antibodies</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - blood</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Natalizumab - therapeutic use</topic><topic>Neurochemistry</topic><topic>Neurology</topic><topic>Oxidative stress</topic><topic>Oxidative Stress - drug effects</topic><topic>Pathogenesis</topic><topic>Rodents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adamczyk-Sowa, Monika</creatorcontrib><creatorcontrib>Kasperczyk, Sławomir</creatorcontrib><creatorcontrib>Wawrzyniak, Sławomir</creatorcontrib><creatorcontrib>Adamczyk, Bożena</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oxidative medicine and cellular longevity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adamczyk-Sowa, Monika</au><au>Kasperczyk, Sławomir</au><au>Wawrzyniak, Sławomir</au><au>Adamczyk, Bożena</au><au>Romero, Francisco J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy</atitle><jtitle>Oxidative medicine and cellular longevity</jtitle><addtitle>Oxid Med Cell Longev</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>2017</volume><issue>2017</issue><spage>1</spage><epage>12</epage><pages>1-12</pages><issn>1942-0900</issn><eissn>1942-0994</eissn><abstract>Objectives. The assessment of oxidative stress (OS) in serum relapsing-remitting multiple sclerosis patients treated with II-line immunomodulatory therapy (fingolimod, natalizumab) compared to newly diagnosed patients (de novo group) treated with interferon (IFN) beta and controls. The relationship between OS parameters and gender, age, disease duration, Expanded Disability Status Scale, annualized relapse rate, MRI lesions in patients treated with II-line. Materials and Methods. One hundred and twenty-one patients with RRMS were enrolled in the study. Patients were divided into groups: de novo group, IFN, fingolimod (FG), natalizumab (NT), and controls. Lipid hydroperoxides (LHP), malondialdehyde (MDA), lipofuscin (LPS), and total oxidative status (TOS) were determined. Results. LHP, MDA, and TOS were lower in NT and FG groups compared to the de novo group. Levels of OS were different between NT and FG patients and the IFN group. Women treated with FG and NT had lower MDA, LPH, and TOS than women who were not treated while in men only LPH was lowered. Positive correlations were found between MDA, LHP, TOS, and ARR in the NT group. Conclusion. The II-line immunomodulatory treatment decreased OS particularly among women. No difference in OS levels was observed between II-line therapy and IFN beta.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>29138683</pmid><doi>10.1155/2017/9625806</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-1641-5350</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1942-0900 |
| ispartof | Oxidative medicine and cellular longevity, 2017-01, Vol.2017 (2017), p.1-12 |
| issn | 1942-0900 1942-0994 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5613460 |
| source | MEDLINE; Wiley Online Library Open Access; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Adult Biological response modifiers Biomarkers Care and treatment Comparative analysis Consent Dentistry Development and progression Female Fingolimod Hydrochloride - therapeutic use Humans Immunomodulation Immunomodulators Immunosuppressive Agents - therapeutic use Interferon Investigations Lipid Peroxides - blood Lipofuscin - blood Male Malondialdehyde - blood Medical research Medicine, Experimental Monoclonal antibodies Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - blood Multiple Sclerosis, Relapsing-Remitting - drug therapy Natalizumab - therapeutic use Neurochemistry Neurology Oxidative stress Oxidative Stress - drug effects Pathogenesis Rodents |
| title | The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T21%3A56%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Evaluation%20of%20Oxidative%20Stress%20Parameters%20in%20Serum%20Patients%20with%20Relapsing-Remitting%20Multiple%20Sclerosis%20Treated%20with%20II-Line%20Immunomodulatory%20Therapy&rft.jtitle=Oxidative%20medicine%20and%20cellular%20longevity&rft.au=Adamczyk-Sowa,%20Monika&rft.date=2017-01-01&rft.volume=2017&rft.issue=2017&rft.spage=1&rft.epage=12&rft.pages=1-12&rft.issn=1942-0900&rft.eissn=1942-0994&rft_id=info:doi/10.1155/2017/9625806&rft_dat=%3Cgale_pubme%3EA555850923%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1942142294&rft_id=info:pmid/29138683&rft_galeid=A555850923&rfr_iscdi=true |